tiprankstipranks
Climb Bio (CLYM)
NASDAQ:CLYM
US Market
CLYM
Climb Bio
RESEARCH TOOLSreports

Climb Bio (CLYM) Stock Forecast & Price Target

695 Followers
See the Price Targets and Ratings of:

CLYM Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Climb
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CLYM Stock 12 Month Forecast

Average Price Target

$16.67
▲(142.65% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Climb Bio in the last 3 months. The average price target is $16.67 with a high forecast of $26.00 and a low forecast of $8.00. The average price target represents a 142.65% change from the last price of $6.87.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","27":"$27","6.75":"$6.75","13.5":"$13.5","20.25":"$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.75,13.5,20.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.95,8.415384615384616,9.880769230769232,11.346153846153847,12.811538461538461,14.276923076923078,15.742307692307694,17.20769230769231,18.673076923076923,20.138461538461538,21.603846153846156,23.06923076923077,24.534615384615385,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.95,7.697692307692308,8.445384615384615,9.193076923076923,9.94076923076923,10.688461538461539,11.436153846153847,12.183846153846154,12.931538461538462,13.67923076923077,14.426923076923078,15.174615384615386,15.922307692307694,{"y":16.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.95,7.030769230769231,7.111538461538462,7.1923076923076925,7.273076923076923,7.353846153846154,7.434615384615385,7.515384615384615,7.596153846153847,7.676923076923077,7.757692307692308,7.838461538461539,7.9192307692307695,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$26.00Average Price Target$16.67Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on CLYM
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (NASDAQ: TARS), Climb Bio (NASDAQ: CLYM) and Boston Scientific (NYSE: BSX)
B. Riley Securities Analyst forecast on CLYM
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$26
Buy
278.46%
Upside
Initiated
03/24/26
Climb Bio initiated with a Buy at B. RileyClimb Bio initiated with a Buy at B. Riley
Truist Financial Analyst forecast on CLYM
Danielle Brill
Truist Financial
Truist Financial
$17
Buy
147.45%
Upside
Initiated
03/18/26
Climb Bio initiated with a Buy at TruistClimb Bio initiated with a Buy at Truist
H.C. Wainwright Analyst forecast on CLYM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$11→$15
Buy
118.34%
Upside
Reiterated
03/10/26
Climb Bio price target raised to $15 from $11 at H.C. WainwrightClimb Bio price target raised to $15 from $11 at H.C. Wainwright
Raymond James Analyst forecast on CLYM
Christopher Raymond
Raymond James
Raymond James
$25
Buy
263.90%
Upside
Initiated
03/10/26
Climb Bio initiated with a Strong Buy at Raymond JamesClimb Bio initiated with a Strong Buy at Raymond James
Leerink Partners Analyst forecast on CLYM
Thomas Smith
Leerink Partners
Leerink Partners
$10
Buy
45.56%
Upside
Reiterated
03/06/26
Analysts' Top Healthcare Picks: Climb Bio (CLYM), Ibio (IBIO)
Wedbush Analyst forecast on CLYM
Laura Chico
Wedbush
Wedbush
$12→$14
Buy
103.78%
Upside
Reiterated
03/06/26
Climb Bio initiated with an Outperform at WedbushClimb Bio initiated with an Outperform at Wedbush
BTIG Analyst forecast on CLYM
Julian Harrison
BTIG
BTIG
$8
Buy
16.45%
Upside
Reiterated
03/05/26
Analysts Offer Insights on Healthcare Companies: Climb Bio (NASDAQ: CLYM), ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)
Robert W. Baird Analyst forecast on CLYM
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$9→$12
Buy
74.67%
Upside
Reiterated
03/05/26
Climb Bio price target raised to $12 from $9 at BairdClimb Bio price target raised to $12 from $9 at Baird
Piper Sandler Analyst forecast on CLYM
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$23
Buy
234.79%
Upside
Initiated
02/13/26
Climb Bio initiated with an Overweight at Piper SandlerClimb Bio initiated with an Overweight at Piper Sandler
Oppenheimer Analyst forecast on CLYM
Leland Gershell
Oppenheimer
Oppenheimer
$10
Buy
45.56%
Upside
Reiterated
11/10/25
Oppenheimer Sticks to Its Buy Rating for Climb Bio (CLYM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on CLYM
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (NASDAQ: TARS), Climb Bio (NASDAQ: CLYM) and Boston Scientific (NYSE: BSX)
B. Riley Securities Analyst forecast on CLYM
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$26
Buy
278.46%
Upside
Initiated
03/24/26
Climb Bio initiated with a Buy at B. RileyClimb Bio initiated with a Buy at B. Riley
Truist Financial Analyst forecast on CLYM
Danielle Brill
Truist Financial
Truist Financial
$17
Buy
147.45%
Upside
Initiated
03/18/26
Climb Bio initiated with a Buy at TruistClimb Bio initiated with a Buy at Truist
H.C. Wainwright Analyst forecast on CLYM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$11→$15
Buy
118.34%
Upside
Reiterated
03/10/26
Climb Bio price target raised to $15 from $11 at H.C. WainwrightClimb Bio price target raised to $15 from $11 at H.C. Wainwright
Raymond James Analyst forecast on CLYM
Christopher Raymond
Raymond James
Raymond James
$25
Buy
263.90%
Upside
Initiated
03/10/26
Climb Bio initiated with a Strong Buy at Raymond JamesClimb Bio initiated with a Strong Buy at Raymond James
Leerink Partners Analyst forecast on CLYM
Thomas Smith
Leerink Partners
Leerink Partners
$10
Buy
45.56%
Upside
Reiterated
03/06/26
Analysts' Top Healthcare Picks: Climb Bio (CLYM), Ibio (IBIO)
Wedbush Analyst forecast on CLYM
Laura Chico
Wedbush
Wedbush
$12→$14
Buy
103.78%
Upside
Reiterated
03/06/26
Climb Bio initiated with an Outperform at WedbushClimb Bio initiated with an Outperform at Wedbush
BTIG Analyst forecast on CLYM
Julian Harrison
BTIG
BTIG
$8
Buy
16.45%
Upside
Reiterated
03/05/26
Analysts Offer Insights on Healthcare Companies: Climb Bio (NASDAQ: CLYM), ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)
Robert W. Baird Analyst forecast on CLYM
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$9→$12
Buy
74.67%
Upside
Reiterated
03/05/26
Climb Bio price target raised to $12 from $9 at BairdClimb Bio price target raised to $12 from $9 at Baird
Piper Sandler Analyst forecast on CLYM
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$23
Buy
234.79%
Upside
Initiated
02/13/26
Climb Bio initiated with an Overweight at Piper SandlerClimb Bio initiated with an Overweight at Piper Sandler
Oppenheimer Analyst forecast on CLYM
Leland Gershell
Oppenheimer
Oppenheimer
$10
Buy
45.56%
Upside
Reiterated
11/10/25
Oppenheimer Sticks to Its Buy Rating for Climb Bio (CLYM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Climb Bio

3 Months
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+125.93%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +125.93% per trade.
1 Year
Leland GershellOppenheimer
Success Rate
3/3 ratings generated profit
100%
Average Return
+315.30%
Copying Leland Gershell's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +315.30% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+315.30%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +315.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CLYM Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
4
2
3
8
8
Buy
3
4
2
7
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
6
5
15
13
In the current month, CLYM has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CLYM average Analyst price target in the past 3 months is 16.67.
Each month's total comprises the sum of three months' worth of ratings.

CLYM Financial Forecast

CLYM Earnings Forecast

Next quarter’s earnings estimate for CLYM is -$0.29 with a range of -$0.57 to -$0.22. The previous quarter’s EPS was -$0.26. CLYM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CLYM has Performed in-line its overall industry.
Next quarter’s earnings estimate for CLYM is -$0.29 with a range of -$0.57 to -$0.22. The previous quarter’s EPS was -$0.26. CLYM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CLYM has Performed in-line its overall industry.
No data currently available

CLYM Sales Forecast

Next quarter’s sales forecast for CLYM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CLYM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CLYM has Performed in-line its overall industry.
Next quarter’s sales forecast for CLYM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CLYM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CLYM has Performed in-line its overall industry.

CLYM Stock Forecast FAQ

What is CLYM’s average 12-month price target, according to analysts?
Based on analyst ratings, Climb Bio’s 12-month average price target is 16.67.
    What is CLYM’s upside potential, based on the analysts’ average price target?
    Climb Bio has 142.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CLYM a Buy, Sell or Hold?
          Climb Bio has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Climb Bio’s price target?
            The average price target for Climb Bio is 16.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $26.00 ,the lowest forecast is $8.00. The average price target represents 142.65% Increase from the current price of $6.87.
              What do analysts say about Climb Bio?
              Climb Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of CLYM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.